

## USAMMDA Mission

The USAMMDA **Mission** is to develop and manage medical materiel to protect and sustain the Warfighter on point for the Nation.

## For more information about USAMMDA

Visit our website:

[www.usammda.army.mil](http://www.usammda.army.mil)

# USAMMDA

U.S. Army Medical Materiel Development Activity



*Developing Quality Medical Products  
for U.S. Forces*

## Adenovirus Vaccine



## USAMMDA Vision

The USAMMDA **Vision** is to integrate with USAMRMC, Federal agencies, and the DoD, as part of the joint biomedical research and materiel community, to focus on delivering the best medical solutions for today and tomorrow.

Our products are an integral part of the DoD Force Health Protection Program, to include vaccines, drugs, and medical devices, to prevent, diagnose, and treat infectious diseases, combat-related casualties, and CBRNE threats.

Our products enhance far-forward medical care across the full spectrum of health care missions worldwide.

## Or contact us at:

### USAMMDA

1430 Veterans Drive, Fort Detrick, MD 21702

301.619.7056

[usammda.pao@amedd.army.mil](mailto:usammda.pao@amedd.army.mil)

### Pharmaceutical Systems Project Management Office

Product Manager

301.619.4821

## U.S. Army Medical Research and Materiel Command

*Protect the Warrior, Sustain the Force*


Last updated: June 16, 2011

The adenovirus vaccine is two orally administered, enteric-coated tablets containing live adenovirus serotypes 4 or 7

## The Adenovirus Vaccine

The Adenovirus Vaccine has been used by the Department of Defense to prevent adenovirus-related acute respiratory disease in military recruits during basic training, while living in barracks-type environments. Since the adenovirus can spread via direct contact, airborne transmission and droplet transmission, the close quarters of recruit life make them highly susceptible to exposure.

Adenovirus infections in military recruits are associated with pharyngitis, conjunctivitis, rhinitis and pneumonia. These illnesses often lead to missed training and some recruits have to repeat parts of the training cycle.



## Distribution

The Adenovirus Vaccine is two orally administered, enteric-coated tablet containing live adenovirus serotypes 4 or 7.

Each initial-entry recruit will receive a one-time dose of both serotypes, along with their other immunizations, during in-processing.

## Vaccine Development

A contract to develop and manufacture the types 4 and 7 adenovirus vaccine was awarded to Barr Pharmaceuticals in 2001. In July 2004, Barr submitted the Investigational New Drug (IND) application to the FDA. Clinical studies were carried out jointly by the Army and Navy. The Phase 1 clinical trial was completed in April 2005 at Fort Sam Houston, TX. A successful Phase 3 clinical trial began in September 2006 at Ft. Jackson, SC and Naval Training Center, Great Lakes, IL. A Biological License Application was submitted to the FDA in 2008 and approved in March 2011.



DoD and Barr production staff at the Barr facility in Forest, VA in March 2007.



Representatives from USAMMDA observe the processes and equipment for manufacturing the Adenovirus Vaccine tablets at the new facility in Forest, VA.

## Product Timeline

